Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReCor Deal Underscores RDN Revival – But Also Reason For Backing Medtech?

Executive Summary

Certain VCs are becoming reluctant to invest in medtech, citing difficulties such as a shrinking pool of buyers and increasing regulatory challenges. But Sofinnova Partners has successfully sold a medical device portfolio company – and one that is in a difficult field like renal denervation, no less – to a Japanese buyer. Antoine Papiernik, managing partner at the French VC, explains how persevering with a renal denervation technology paid-off and gives his perspective on whether medtech is still a space worth investing in.

Advertisement

Related Content

Work With Patients To Design Trials For Anti-Hypertensive Devices, FDA Advisors Suggest
Hypertension Devices Will Get US FDA Panel Focus
Boston Scientific Gulps Down Claret After Cryterion, In Double-Whammy July
Abingworth Closes 12th Life Sciences Fund ABV VII At $315M
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel